Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Naim Alkhouri, MD
Advertisement
Naim Alkhouri, MD, FAASLD, DABOM, is the chief of transplant hepatology and director of the Steatotic Liver Program at Arizona Liver Health.
Articles by Naim Alkhouri, MD
Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase patient access, but also improve the overall wellbeing, experience, and outcomes for this population.
The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.
Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
4
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
5
